Reimbursement for AI in echocardiography is now a reality.
EchoGo® Heart Failure is one of the first AI technologies in echocardiography to move from clinical validation into reimbursed clinical practice, helping healthcare systems integrate AI-powered HFpEF detection into routine care pathways.
FDA-cleared | CPT-supported | Live in leading U.S. hospitals
Reimbursement built into existing care pathways.
Ultromics is building one of the world’s most innovative and trusted AI platforms for cardiovascular disease detection, helping clinicians identify complex heart disease, such as HFpEF and cardiac amyloidosis, early from routine echocardiography.
EchoGo® Heart Failure is supported by CPT code 0932T, enabling AI-assisted HFpEF detection to integrate into established echocardiography billing workflows.
EchoGo® Heart Failure provides augmentative AI-assisted analysis to support physician interpretation and patient management decisions.
The platform analyzes a single apical four-chamber view from routine echocardiography to help identify patients suggestive of HFpEF.
EchoGo® Heart Failure is intended to support clinical interpretation and should not be used as a standalone diagnostic decision-making tool.
Designed around existing echocardiography workflows.
CMS considers EchoGo® Heart Failure a distinct adjunctive stand-alone AI analysis service, separate from the transthoracic echocardiogram (TTE).
Routine transthoracic echocardiography is performed as normal. EchoGo® Heart Failure then provides AI-assisted analysis to support physician interpretation and patient management decisions.
No additional hardware. No new scanning views. No workflow disruption.
Applicable workflows include:
- Complete transthoracic echocardiography (TTE)
- Limited or follow-up TTE studies
- Outpatient cardiovascular imaging
- Inpatient echocardiography assessment
Reimbursement at a glance
Ultromics is building one of the world’s most innovative and trusted AI platforms for cardiovascular disease detection, helping clinicians identify complex heart disease, such as HFpEF and cardiac amyloidosis, early from routine echocardiography.
-
check_boxCPT code0932T
-
check_boxCategoryCategory III CPT code
-
check_boxUseAI-assisted detection of HFpEF from echocardiography
-
check_boxNational average outpatient reimbursement~$316 per analysis
-
check_boxCare settingsOutpatient • Inpatient • Physician office
-
check_boxWorkflowWorks alongside standard transthoracic echocardiography (TTE)
-
check_boxDeploymentNo additional scanning protocol required
Hospital outpatient
EchoGo® Heart Failure is reimbursed under the Outpatient Prospective Payment System (OPPS) using CPT code 0932T.
National average reimbursement
Payment may vary based on locality and payer structure.
Hospital inpatient
For inpatient settings, reimbursement is bundled within the inpatient stay.
Physician setting
CPT code 0932T is currently carrier-priced.
Expanding beyond Medicare pathways.
Reimbursement opportunities may also extend across Medicare Advantage and commercial insurers depending on payer contracts and care setting.
Commercial reimbursement rates may exceed standard Medicare outpatient reimbursement depending on payer agreements and regional contracts.
As healthcare systems increasingly adopt AI-enabled diagnostics, reimbursement pathways continue evolving across cardiovascular care.
Most AI solutions stop at clinical validation.
Enabling scaled clinical adoption
Ultromics has gone further, working across clinical evidence, regulatory clearance and reimbursement pathways to support real-world adoption at scale
From code to billing
EchoGo® Heart Failure is one of the first AI technologies in echocardiography to move through the full pathway, from code creation to real-world billing.
Paving the way for AI HFpEF reimbursement
Ultromics helped establish the reimbursement pathway for AI-enabled HFpEF detection from echocardiography, supporting real-world deployment across U.S. healthcare systems.
Moving beyond AI experimentation
This helps healthcare systems move from AI experimentation toward scalable clinical deployment.
Built to support clinical decision-making.
As with all diagnostic services, reimbursement depends on medical necessity, physician documentation and appropriate clinical use
Supporting clinical indications may include:
- Shortness of breath
- Chest discomfort
- Palpitations
- Lower extremity edema
- Syncope or pre-syncope
- Suspected hypertensive heart disease
- Other signs suggestive of possible heart failure
EchoGo® Heart Failure supports physician interpretation and should be incorporated within the broader clinical assessment and patient care pathway.
Reimbursement helps accelerate adoption.
EchoGo® Heart Failure was designed to support both clinical and operational value across healthcare systems.
The platform helps support:
- Earlier HFpEF detection
- Improved diagnostic confidence
- Identification of treatable patients
- Scalable deployment across care settings
- Clearer operational and reimbursement pathways for adoption
This allows providers to integrate AI-powered cardiovascular detection into routine clinical care with a clearer path toward long-term implementation.
Explore reimbursement pathways with Ultromics.
Speak with our team to learn how EchoGo® Heart Failure fits into clinical workflows, reimbursement pathways and scalable operational deployment.